Constitutional CHEK2 mutations are infrequent in early-onset and familial breast/ovarian cancer patients from Pakistan

BackgroundLess than 20% of Pakistani women with early-onset or familial breast/ovarian cancer harbor germ line mutations in the high-penetrance genes BRCA1, BRCA2 and TP53. Thus, mutations in other genes confer genetic susceptibility to breast cancer, of which CHEK2 is a plausible candidate. CHEK2 encodes a checkpoint kinase, involved in response to DNA damage.MethodsIn the present study we assessed the prevalence of CHEK2 germ line mutations in 145 BRCA1/2-negative early-onset and familial breast/ovarian cancer patients from Pakistan (Group 1). Mutation analysis of the complete CHEK2 coding region was performed using denaturing high-performance liquid chromatography analysis, followed by DNA sequencing of variant fragments.ResultsTwo potentially deleterious missense mutations, c.275C>G (p.P92R) and c.1216C>T, (p.R406C), were identified (1.4%). The c.275C>G mutation is novel and has not been described in other populations. It was detected in a 30-year-old breast cancer patient with a family history of breast and multiple other cancers. The c.1216C>T mutation was found in a 34-year-old ovarian cancer patient from a family with two breast cancer cases. Both mutations were not detected in 229 recently recruited BRCA1/2-negative high risk patients (Group 2).ConclusionOur findings suggest that CHEK2 mutations may not contribute significantly to breast/ovarian cancer risk in Pakistani women.

[1]  M. Schutte,et al.  Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant , 2004, Journal of Medical Genetics.

[2]  J. Klijn,et al.  The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. , 2003, Cancer research.

[3]  D. Horsman,et al.  Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study. , 2008, Cancer research.

[4]  P. Ang,et al.  CHEK2*1100delC screening of Asian women with a family history of breast cancer is unwarranted. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Nazneen Rahman,et al.  Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. , 2003, American journal of human genetics.

[6]  Jiri Bartek,et al.  Chk1 and Chk2 kinases in checkpoint control and cancer. , 2003, Cancer cell.

[7]  Kenneth Offit,et al.  Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. , 2005, Human molecular genetics.

[8]  M. Papa,et al.  Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer. , 2007, The Israel Medical Association journal : IMAJ.

[9]  J. Klijn,et al.  The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. , 2003, American journal of human genetics.

[10]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[11]  P. Oefner,et al.  Denaturing high‐performance liquid chromatography: A review , 2001, Human mutation.

[12]  J. Benítez,et al.  The breast cancer low‐penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population , 2004, International journal of cancer.

[13]  S. Ahn,et al.  The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation , 2008, Breast Cancer Research and Treatment.

[14]  J. Lubiński,et al.  Pathology of breast cancer in women with constitutional CHEK2 mutations , 2005, Breast Cancer Research and Treatment.

[15]  J. Schleutker,et al.  Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals , 2011, Breast Cancer Research.

[16]  Päivi Heikkilä,et al.  CHEK2 variant I157T may be associated with increased breast cancer risk , 2004, International journal of cancer.

[17]  U. Hamann,et al.  Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients , 2006, International journal of cancer.

[18]  Nazneen Rahman,et al.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.

[19]  J. Lubiński,et al.  Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer , 2012, Breast Cancer Research and Treatment.

[20]  N. Soumittra,et al.  BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India. , 2003, Asian Pacific journal of cancer prevention : APJCP.

[21]  I. Nolte,et al.  Increased CHEK2 1100delC genotype frequency (also) in unselected breast cancer patients. , 2004, Journal of Clinical Oncology.

[22]  S. Teo,et al.  CHEK2*1100delC does not contribute to risk to breast cancer among Malay, Chinese and Indians in Malaysia , 2009, Familial Cancer.

[23]  P. Souček,et al.  Analysis of CHEK2 FHA domain in Czech patients with sporadic breast cancer revealed distinct rare genetic alterations , 2008, Breast Cancer Research and Treatment.

[24]  S. Bojesen,et al.  CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients , 2012, Familial Cancer.

[26]  N. Mailand,et al.  The ATM–Chk2–Cdc25A checkpoint pathway guards against radioresistant DNA synthesis , 2001, Nature.

[27]  A. Jakubowska,et al.  Estrogen receptor status in CHEK2‐positive breast cancers: implications for chemoprevention , 2009, Clinical genetics.

[28]  David I. Smith,et al.  Mutations in CHEK2 associated with prostate cancer risk. , 2003, American journal of human genetics.

[29]  A. Hollestelle,et al.  Discovering moderate-risk breast cancer susceptibility genes. , 2010, Current opinion in genetics & development.

[30]  S. Narod,et al.  CHEK2 mutation and hereditary breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Jong-Soo Lee,et al.  hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response , 2000, Nature.

[32]  T. Halazonetis,et al.  Chk 2 / hCds 1 functions as a DNA damage checkpoint in G 1 by stabilizing p 53 , 2022 .

[33]  Rochelle L. Garcia,et al.  Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing , 2011, Proceedings of the National Academy of Sciences.

[34]  J. Lubiński,et al.  CHEK2 is a multiorgan cancer susceptibility gene. , 2004, American journal of human genetics.

[35]  S. Moreno,et al.  Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1 , 1998, Nature.

[36]  N. Soumittra,et al.  Molecular genetics analysis of hereditary breast and ovarian cancer patients in India , 2009, Hereditary cancer in clinical practice.

[37]  P. Devilee,et al.  Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia , 2007, Familial Cancer.

[38]  Z. Shao,et al.  [CHEK2 c.1100delC may not contribute to genetic background of hereditary breast cancer from Shanghai of China]. , 2006, Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics.

[39]  Yuntao Xie,et al.  A recurrent CHEK2 p.H371Y mutation is associated with breast cancer risk in Chinese women , 2011, Human mutation.

[40]  Patricia L. Harris,et al.  Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts , 2007, International journal of cancer.

[41]  O. Kallioniemi,et al.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. , 2002, American journal of human genetics.

[42]  T. Halazonetis,et al.  Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. , 2000, Genes & development.

[43]  R. Eeles,et al.  A robust method for detecting CHK2/RAD53 mutations in genomic DNA , 2002, Human mutation.

[44]  W. Chen,et al.  Breast cancer low-penetrance allele 1100delC in the CHEK2 gene: Not present in the Chinese familial breast cancer population , 2008, Advances in therapy.

[45]  A. Meindl,et al.  Limited relevance of the CHEK2 gene in hereditary breast cancer , 2004, International journal of cancer.

[46]  J. Hopper,et al.  Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study , 2011, Breast Cancer Research.

[47]  A. Jakubowska,et al.  A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland , 2007, Breast Cancer Research and Treatment.

[48]  Nazneen Rahman,et al.  CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. , 2004, American journal of human genetics.

[49]  T. Walsh,et al.  Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. , 2006, JAMA.

[50]  W. Foulkes,et al.  Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women , 2008, BMC Cancer.

[51]  T. Dörk,et al.  Association of two mutations in the CHEK2 gene with breast cancer , 2005, International journal of cancer.

[52]  Y. Bignon,et al.  CHEK2 contribution to hereditary breast cancer in non-BRCA families , 2011, Breast Cancer Research.

[53]  S. Elledge,et al.  Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. , 2000, Proceedings of the National Academy of Sciences of the United States of America.